Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática

Detalhes bibliográficos
Autor(a) principal: Joana Alexandra Conde Gonçalves
Data de Publicação: 2021
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/134561
Resumo: Background: Kidney biopsies play a crucial role in diagnosing many renal conditions in native and transplanted kidneys. Despite considered safe procedures, the risk of bleeding is one of the main concerns - the use of antiaggregants can add to this risk. Due to aspirins' widespread use, the authors aimed to establish the best pre-procedural strategy regarding its cessation in patients proposed for kidney biopsy. Methods: The authors conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two electronic databases were used (MEDLINE and SCOPUS). The defined search criteria were coded into queries specific to each database. Due to significant heterogeneity in methodology, participant selection, and reported outcome measures, results were presented qualitatively. Results: Ten studies were selected, including 21624 biopsies in total. One study reviewing allograft kidney biopsies suggested high-dose aspirin within three days of the biopsy was associated with an increased risk of bleeding, and another reported higher bleeding rates in aspirin-treated patients. One study pertaining to native kidney biopsies described a higher risk of minor bleeding complications in patients under concurrent aspirin use. None of the other selected articles found an association between aspirin exposure and bleeding risk. Conclusion: This systematic review suggests that aspirin therapy is not associated with renal biopsy major bleeding complications or related death. In patients with high cardiovascular risk, in whom the risks of suspending aspirin therapy outweigh the bleeding risk, a kidney biopsy may still be performed relatively safely.
id RCAP_9a8d3456e0be51a65cf79e81f6023405
oai_identifier_str oai:repositorio-aberto.up.pt:10216/134561
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemáticaMedicina clínicaClinical medicineBackground: Kidney biopsies play a crucial role in diagnosing many renal conditions in native and transplanted kidneys. Despite considered safe procedures, the risk of bleeding is one of the main concerns - the use of antiaggregants can add to this risk. Due to aspirins' widespread use, the authors aimed to establish the best pre-procedural strategy regarding its cessation in patients proposed for kidney biopsy. Methods: The authors conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two electronic databases were used (MEDLINE and SCOPUS). The defined search criteria were coded into queries specific to each database. Due to significant heterogeneity in methodology, participant selection, and reported outcome measures, results were presented qualitatively. Results: Ten studies were selected, including 21624 biopsies in total. One study reviewing allograft kidney biopsies suggested high-dose aspirin within three days of the biopsy was associated with an increased risk of bleeding, and another reported higher bleeding rates in aspirin-treated patients. One study pertaining to native kidney biopsies described a higher risk of minor bleeding complications in patients under concurrent aspirin use. None of the other selected articles found an association between aspirin exposure and bleeding risk. Conclusion: This systematic review suggests that aspirin therapy is not associated with renal biopsy major bleeding complications or related death. In patients with high cardiovascular risk, in whom the risks of suspending aspirin therapy outweigh the bleeding risk, a kidney biopsy may still be performed relatively safely.2021-05-122021-05-12T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://hdl.handle.net/10216/134561TID:202849040engJoana Alexandra Conde Gonçalvesinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T16:09:19Zoai:repositorio-aberto.up.pt:10216/134561Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:38:20.211794Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
title Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
spellingShingle Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
Joana Alexandra Conde Gonçalves
Medicina clínica
Clinical medicine
title_short Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
title_full Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
title_fullStr Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
title_full_unstemmed Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
title_sort Efeitos da aspirina nas complicações hemorrágicas da biópsia renal - uma revisão sistemática
author Joana Alexandra Conde Gonçalves
author_facet Joana Alexandra Conde Gonçalves
author_role author
dc.contributor.author.fl_str_mv Joana Alexandra Conde Gonçalves
dc.subject.por.fl_str_mv Medicina clínica
Clinical medicine
topic Medicina clínica
Clinical medicine
description Background: Kidney biopsies play a crucial role in diagnosing many renal conditions in native and transplanted kidneys. Despite considered safe procedures, the risk of bleeding is one of the main concerns - the use of antiaggregants can add to this risk. Due to aspirins' widespread use, the authors aimed to establish the best pre-procedural strategy regarding its cessation in patients proposed for kidney biopsy. Methods: The authors conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two electronic databases were used (MEDLINE and SCOPUS). The defined search criteria were coded into queries specific to each database. Due to significant heterogeneity in methodology, participant selection, and reported outcome measures, results were presented qualitatively. Results: Ten studies were selected, including 21624 biopsies in total. One study reviewing allograft kidney biopsies suggested high-dose aspirin within three days of the biopsy was associated with an increased risk of bleeding, and another reported higher bleeding rates in aspirin-treated patients. One study pertaining to native kidney biopsies described a higher risk of minor bleeding complications in patients under concurrent aspirin use. None of the other selected articles found an association between aspirin exposure and bleeding risk. Conclusion: This systematic review suggests that aspirin therapy is not associated with renal biopsy major bleeding complications or related death. In patients with high cardiovascular risk, in whom the risks of suspending aspirin therapy outweigh the bleeding risk, a kidney biopsy may still be performed relatively safely.
publishDate 2021
dc.date.none.fl_str_mv 2021-05-12
2021-05-12T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/134561
TID:202849040
url https://hdl.handle.net/10216/134561
identifier_str_mv TID:202849040
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136290841559041